Switching From PI to RALtegravir in HIV Stable Patients
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesis is that switching from a ritonavir-boosted PI to raltegravir may
be associated with an at least non-inferior effectiveness, virological response and safety,
and even a better tolerability profile with regard to lipid metabolism, insulin resistance,
body fat distribution as compared with continuation of the baseline regimen in HIV-1
seropositive males or females at least 18 years of age and older on ritonavir-boosted PI plus
at least 2 other drugs and plasma viral RNA below 50 copies/mL.